Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Recurrence × Epirubicin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 15 Triple Negative Breast Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 2 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Non-Muscle Invasive Bladder Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma, T-Cell, Peripheral 1 Inflammatory Breast Neoplasms 1 HR+/HER2- Breast Cancer 1 Epstein-Barr Virus Infections 1 Congenital Abnormalities 1 Carcinoma, Adenoid Cystic 1 CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1

Interventions

Cyclophosphamide 38 Dexamethasone 31 venetoclax 28 fludarabine 27 pembrolizumab 20 pomalidomide 17 Rituximab 17 Gemcitabine 16 Lenalidomide 14 Cytarabine 14 carfilzomib 11 Nivolumab 11 fludarabine phosphate 10 Temozolomide 10 Etoposide 10 Calcium Dobesilate 10 Azacitidine 10 glofitamab 9 daratumumab 9 Injections 9 obinutuzumab 8 Cisplatin 8 ibrutinib 7 cemiplimab 7 Carboplatin 7 Capecitabine 7 Bevacizumab 7 zanubrutinib 6 selinexor 6 ruxolitinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡